These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 7333068)

  • 21. [Evaluation of the therapeutic effects of silymarin].
    Margaroli P; Rossi M; Arcabasso GD; Cosini I; Malacrida C
    Clin Ter; 1980 Dec; 95(6):663-72. PubMed ID: 7214856
    [No Abstract]   [Full Text] [Related]  

  • 22. [Correction of dyslipoproteinemia in middle-aged and elderly patients with atherosclerosis using Essentiale in combination with adebit].
    Korkushko OV; Bogatskaia LN; Kovalenko AN; Novikova SN; Kotko DN
    Vrach Delo; 1989 Aug; (8):19-22. PubMed ID: 2588515
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tolerability and side-effects of bis-(hydroxy-2-ethylthio)-1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia].
    Colombo L; Monarca A; Goldberg D; Zanetta R
    Clin Ter; 1979 Oct; 91(2):155-71. PubMed ID: 540479
    [No Abstract]   [Full Text] [Related]  

  • 24. [Use of silymarin in the treatment of alcoholic hepatic steatosis].
    Canini F; Bartolucci L; Cristallini E; Gradoli C; Rossi A; Ribacchi R; Valori C
    Clin Ter; 1985 Aug; 114(4):307-14. PubMed ID: 4053546
    [No Abstract]   [Full Text] [Related]  

  • 25. Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Artery; 1980; 8(2):113-9. PubMed ID: 7458676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
    Rudolph G; Endele R; Senn M; Stiehl A
    Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Bile acids before and after administration of branched-chain amino acids in acute hepatitis].
    Iaquinto G; Guarino A; Taccone W; Imparato L; Ambrosone L; Giardullo N; Di Scala A; De Renzi E; Pasquale L; Maione A
    Minerva Dietol Gastroenterol; 1987; 33(3):217-21. PubMed ID: 3670671
    [No Abstract]   [Full Text] [Related]  

  • 28. [Immunomodulator effect of silymarin therapy in chronic alcoholic liver diseases].
    Deák G; Müzes G; Láng I; Niederland V; Nékám K; Gonzalez-Cabello R; Gergely P; Fehér J
    Orv Hetil; 1990 Jun; 131(24):1291-2, 1295-6. PubMed ID: 2195425
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Various characteristics of lipid metabolism disorders in obesity].
    Kalmykov ZA
    Klin Med (Mosk); 1984 Aug; 62(8):107-9. PubMed ID: 6492701
    [No Abstract]   [Full Text] [Related]  

  • 30. [Uses of silymarin in the treatment of symptomatic hepatic porphyria (author's transl)].
    Kordac V; Kaláb M
    Cas Lek Cesk; 1977 Apr; 116(13):407-10. PubMed ID: 861998
    [No Abstract]   [Full Text] [Related]  

  • 31. Serum profile of non-esterified fatty acids (NEFA) in patients with hyperlipoproteinemia under xantinol--nicotinate (XN) medication.
    Haacke H; Parwaresch MR; Mäder C
    Atherosclerosis; 1980 Sep; 37(1):77-85. PubMed ID: 7426090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Evaluation of a sulfomucopolysaccharide (3GS) in the treatment of hyperlipoproteinemias].
    Palmieri G; Perego M; Nazzari M; Casalini F
    Clin Ter; 1982 Jun; 101(6):603-14. PubMed ID: 7128029
    [No Abstract]   [Full Text] [Related]  

  • 33. [A two-center study on the effects of silymarin in pregnant women and adult patients with so-called minor hepatic insufficiency].
    Giannola C; Buogo F; Forestiere G; Scaffidi L; Ferrigno V; Scaffidi A
    Clin Ter; 1985 Jul; 114(2):129-35. PubMed ID: 4053531
    [No Abstract]   [Full Text] [Related]  

  • 34. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ; Gutiérrez Martín M; del Río Ligorit A; Casasnovas Lenguas JA; Cornudella Lacasa R
    Med Clin (Barc); 1982 May; 78(9):380-5. PubMed ID: 7047926
    [No Abstract]   [Full Text] [Related]  

  • 35. Liver cell protection in toxic liver lesion.
    Fehér J; Cornides A; Pál J; Láng I; Csomós G
    Acta Physiol Hung; 1989; 73(2-3):285-91. PubMed ID: 2596318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
    Noseda G; Fragiacomo C; Weidmann P; Bachmann C
    Schweiz Med Wochenschr; 1980 Dec; 110(49):1875-7. PubMed ID: 7455660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study of metabolic and clinical effects of polyunsaturated fatty acids omega-3 from "Eicovit" in patients with ischemic heart disease and familial hyperlipoproteinemia].
    Sorokovoĭ KV; Pogozheva AV; Kulakova SN; Lupinovich VL; Karagodina ZV; Levachev MM; Samsonov MA; Vorsanovich EA
    Vopr Pitan; 1998; (2):29-31. PubMed ID: 9680669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Etofylline clofibrate in the treatment of diabetic dyslipidemia: results of a 6-month period of therapy].
    Rajecová E; Klimes I; Seböková E; Rychnavská E; Pleváková L; Linke-Cvrkalová A; Langrová H
    Vnitr Lek; 1995 Oct; 41(10):677-81. PubMed ID: 8578698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Alcoholic hepatopathy. Aspects of drug therapy].
    Del Dotto M; Neri D
    G Clin Med; 1982 Apr; 63(4):228-36. PubMed ID: 7128979
    [No Abstract]   [Full Text] [Related]  

  • 40. Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
    Domingo AJ; Gutiérrez JA; Menéndez JA; Micó L; Muñoz M; de Oya M
    Clin Ther; 1980; 3(3):219-26. PubMed ID: 7459931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.